低剂量氨磺必利联合度洛西汀治疗持续性躯体形式疼痛障碍的疗效与安全性  

Efficacy and safety of low dose amisulpride combined with duloxetine in the treatment of persistent somatic pain disorders

作　　者：辛一帆 李光梅[1] 郑兴华 XIN Yifan;LI Guangmei;ZHENG Xinghua(The Third People's Hospital of Panzhihua,Sichuan province,Panzhihua 617061,China)

机构地区：[1]四川省攀枝花市第三人民医院,617061

出　　处：《临床合理用药杂志》2020年第16期14-16,共3页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察低剂量氨磺必利联合度洛西汀治疗持续性躯体形式疼痛障碍(PSPD)的临床疗效与安全性。方法选取2015年9月-2017年9月于四川省攀枝花市第三人民医院门诊和住院治疗的PSPD患者68例,采用随机数字表法分为研究组和对照组各34例,对照组给予度洛西汀治疗,研究组在对照组治疗的基础上给予低剂量氨磺必利治疗,比较2组患者治疗前、治疗后1、2、4、8周医学结局研究用疼痛量表(MOSPM)、汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、临床疗效总评量表的病情严重程度分量表(CGI-SI)、副反应量表(TESS)评分及不良反应发生情况。结果治疗后1周,对照组患者MOSPM、HAMD、HAMA及CGI-SI评分无显著变化(P>0. 05);而研究组MOSPM、HAMD、HAMA及CGI-SI均降低(P <0. 05),且研究组低于对照组(P <0. 05);治疗后2、4、8周,2组患者MOSPM、HAMD、HAMA及CGI-SI评分均降低(P <0. 05),但组间比较差异无统计学意义(P> 0. 05);2组患者TESS评分和不良反应发生率比较差异均无统计学意义(P> 0. 05)。结论低剂量氨磺必利联合度洛西汀治疗PSPD疗效较好,起效快,并不增加药物不良反应,可在临床推广应用。Objective To observe the clinical efficacy and safety of low dose amisulpride combined with duloxetine in the treatment of persistent somatic pain disorder( PSPD). Methods 68 patients with PSPD were selected as outpatients and inpatients in The Third People’s Hospital of Panzhihua,Sichuan Province from September 2015 to September 2017. Random number table method was used to divide the study group and the control group,each of 34 cases,the control group was given duloxetine treatment,and the study group was given low dose amisulpride treatment based on the control group treatment.Before treatment and after 1,2,4 and 8 weeks of treatment,the pain scale( MOSPM),Hamilton Depression Scale( HAMD),Hamilton Anxiety Scale( HAMA),CGI-SI scores and adverse reactions of the two groups of patients were compared.Results 1 week after treatment,there were no significant change in the scores of MOSPM,HAMD,HAMA and CGI-SI in the control group( P > 0. 05);while in the study group,the MOSPM,HAMD,HAMA and CGI-SI all reduced( P < 0. 05),and the study group was lower than the control group( P < 0. 05);2,4,and 8 weeks after treatment,the MOSPM,HAMD,HAMA,and CGI-SI scores of the two groups were all reduced( P < 0. 05),But there were no statistically significant difference between the two groups( P > 0. 05);there were no statistically significant difference between the TESS score and the incidence of adverse reactions between the two groups( P > 0. 05). Conclusion Low dose amisulpride combined with duloxetine is effective in the treatment of PSPD,it has a rapid onset of action and does not increase adverse drug reactions,it can be used in clinical promotion.

关 键 词：持续性躯体形式疼痛障碍 度洛西汀 氨磺必利 低剂量 临床疗效 不良反应 

分 类 号：R749.2[医药卫生—神经病学与精神病学]